Leif Bergsagel, MD
Triplet regimens have been largely established as an optimal approach for treating patients with multiple myeloma who have relapsed. According to Leif Bergsagel, MD, the triplet that stands out from the pack is daratumumab (Darzalex), lenalidomide (Revlimid), and dexamethasone.
The FDA granted approval to this triplet in 2016 based on findings from the phase III POLLUX study.1
Results showed that in patients with relapsed/refractory myeloma, adding daratumumab to lenalidomide and dexamethasone reduced the risk of progression or death by 63% versus lenalidomide and dexamethasone.
... to read the full story